{"id":"W2046284618","doi":"10.1586/era.09.42","title":"Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?","year":2009,"lang":"en","type":"letter","venue":"Expert Review of Anticancer Therapy","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University","funders":"","keywords":"Medicine; Gemcitabine; Bladder cancer; Cisplatin; Neoadjuvant therapy; Cystectomy; Oncology; Chemotherapy; Vinblastine; Regimen; Internal medicine; Urology; Doxorubicin; Cancer; Breast cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000122343,0.001066547,0.002722506,0.0002492574,0.00006844586,0.000024249,0.000370361,0.0004579213,0.0022677],"category_scores_gemma":[0.00001075344,0.0006632239,0.000370493,0.0006566754,0.0002284805,0.0001347932,0.0000216351,0.001005226,0.00001096786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005500728,"about_ca_system_score_gemma":0.001347897,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001196876,"about_ca_topic_score_gemma":0.00009562742,"domain_scores_codex":[0.9956107,0.0001051409,0.0009736581,0.001073886,0.001448747,0.000787867],"domain_scores_gemma":[0.9974947,0.00007736055,0.0006878239,0.001068085,0.0005279629,0.0001440616],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.006625204,0.001409864,0.01883121,0.006678528,0.002825678,0.0004420061,0.002109504,0.000003333164,0.0001140898,0.000003741682,0.6058087,0.3551481],"study_design_scores_gemma":[0.03528885,0.008462476,0.08538204,0.06368153,0.0007151004,0.00002108347,0.00003406301,0.000004997458,0.001931039,0.00002120036,0.802857,0.001600662],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.03472519,0.4176194,0.00003740825,0.5366777,0.0004966352,0.008409693,0.0004862356,0.0001119577,0.001435806],"genre_scores_gemma":[0.003459782,0.3977986,0.0006246276,0.5952975,0.00163221,0.0003890635,0.0003279548,0.0001868554,0.0002834428],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3535474,"threshold_uncertainty_score":0.9995819,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01697129544645139,"score_gpt":0.3053958378885686,"score_spread":0.2884245424421172,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}